The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of its supplies from sources within the US.

The Swiss healthcare firm said that the money will be used to expand its R&D, manufacturing, and distribution operations in the US.

The Australian precision diagnostics firm said it will use the money to support the launch of its proteomic tests in Australia and the US.

The company's investment in diagnostics firm Recipe is part of an effort to develop its DART mass spec tech for therapeutic drug monitoring and drugs of abuse testing.

The company has completed its FDA submission for the system and inked a deal with UAE-based healthcare provider Burjeel Holdings to deploy the system in its facilities.